Alternatives to golimumab
4 same-class SPL records vs golimumab - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.
Brand: Simponi
How to read a high-report FAERS peer set
golimumab ranks in the upper FAERS-volume third of the corpus (#92 of 524); 4 same-class peers are listed for field comparison only. Labeled indication field for golimumab: Simponi Aria treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis.
Top FAERS reaction fields for golimumab total 102,237 reports across 10 reactions, set beside adalimumab, certolizumab, etanercept. Counts are exposure-weighted submissions, not per-patient risk.
About golimumab
Simponi Aria is a medicine that blocks a protein called TNF. It is used to treat certain kinds of arthritis and a spine problem called ankylosing spondylitis.
Used for: Simponi Aria treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. It can help reduce pain, swelling, and stiffness in your joints. For rheumatoid arthritis, you will take this medicine with methotrexate.
4 TNF-Alpha Inhibitor (Biologic) peers (wide set)
adalimumab
RxHumira
Idacio can help adults with rheumatoid arthritis by reducing joint pain and damage. It can also help children (2 years and older) with juvenile idiopathic arthritis. Idacio treats psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.
certolizumab
RxCimzia
Cimzia treats Crohn's disease by easing symptoms. It also helps keep the disease under control in adults. Cimzia can also treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis in adults. It is also used for juvenile idiopathic arthritis in children 2 years and older.
etanercept
RxEnbrel
Enbrel treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis in adults. It also treats juvenile idiopathic arthritis, juvenile psoriatic arthritis and plaque psoriasis in children. Enbrel helps to reduce the signs and symptoms of these conditions, like pain and swelling. It can also help to prevent further damage to your joints.
infliximab
RxRemicade
Inflectra treats Crohn's disease in adults and children (6+). It helps reduce symptoms and keep the disease under control. It also treats ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
golimumab vs adalimumab & certolizumab · FAERS reaction fields
FAERS top-reaction field "Arthralgia" shows the widest count spread between golimumab and adalimumab, certolizumab, etanercept in this extract (38,360-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | golimumab | adalimumab | certolizumab | etanercept |
|---|---|---|---|---|
| Rheumatoid Arthritis | 14,100 | 35,573 | - | 46,175 |
| Pain | 13,403 | 49,062 | - | 43,004 |
| Fatigue | 11,277 | 39,111 | - | 30,269 |
| Joint Swelling | 9,729 | 23,282 | - | 25,430 |
| Arthralgia | 9,679 | 48,039 | - | 44,971 |
| Rash | 9,305 | 25,271 | - | 20,059 |
| Alopecia | 9,271 | - | - | - |
| Abdominal Discomfort | 8,672 | - | - | - |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
golimumab FAERS volume vs class peers
FAERS volume band
golimumab is FAERS corpus rank #92 of 524 (high volume tercile). Top-reaction field total: 102,237.
Frequently Asked Questions
Where does golimumab sit in FAERS report volume vs TNF-Alpha Inhibitor (Biologic) peers? ▼
Registry note: FAERS counts are voluntary reports and do not establish causation or risk rates. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for golimumab: see also the generic vs brand label guide when reading Simponi SPL strings.
Read our methodology - how this data is sourced, computed, and verified.